All systems operational
Q2 2020

Coronary slow flow in patients with impaired glucose tolerance and insulin resistance

Yasser Gaber Metwally · Heba Kamal Sedrak · Inas Fahiem Shaltout
10.1186/s43162-020-00020-1 379 Views 2 Citations
2
Citations
379
Views
Abstract

Abstract
Background
The relationship between coronary slow flow (CSF) and insulin resistance (IR) is still a subject of debate with conflicting data. So the aim was to assess the relationship between IR as measured by IR index (HOMA-IR) and coronary slow flow as measured by the TIMI frame count in patients which (impaired glucose tolerance (IGT) and IR.

Results
Out of 87 patients enrolled, 64 (73.6%) patients were assigned to the IGT group while 23 (26.4%) patients were assigned to the NGT group. There were significantly higher BMI (30.15 ± 2.29 vs 23.90 ± 2.5, P < 0.001), waist circumference (105.05 ± 9.0.06 vs 92.92 ± 16.5, P < 0.001), and frequency of hypertension (60.9% vs 34.8, P = 0.03). Also, there were significantly higher 2-h post-prandial (hPP) glucose (161 ± 30 vs 110 ± 20, P < 0.05), fasting serum insulin level (9.56 ± 2.5 vs 7.03 ± 2.1, P < 0.001), HDL (40 ± 6.5 vs 49 ± 5.6, P < 0.001), HOMA-IR index (2.84 ± 0.03 vs 1.6 ± 0.05, P < 0.05), and mean TIMI frame count (33 ± 5 vs 26 ± 4, P < 0.001) among the IGT group, while HDL was significantly lower in the IGT group (40 ± 6.5 vs 49 ± 5.6, P < 0.001). There was a highly significant positive correlation between TIMI frame count and HOMA-IR (r = 0.43, P < 0.001); predictors that add significance to the model were age > 50 years, hypertension, high waist circumference, HDL < 35, and HOMA-IR. For HOMA-IR (OR 95% CI = 1.9 (1.05–3.49), P = 0.02 demonstrating that HOMA-IR is a powerful independent predictor of high TIMI frame count (Table 4).

Conclusion
IR is an independent risk factor for slow coronary flow in patients with IGT. Those with evident coronary slow flow, IGT should be managed aggressively even before any evidence of frank diabetes. Also, IR workup should be recommended among the other standard workup for those patients; if documented, targeting IR in such patients should be a priority (whenever possible) while selecting medications for comorbid cardiac disease, as well as using interventions targeted against IR should be considered among the other standard management for slow flow.

Cite this Article (APA)
Yasser, G. M., Heba, K. S., Inas, F. S. (2020). Coronary slow flow in patients with impaired glucose tolerance and insulin resistance. The Egyptian Journal of Internal Medicine. https://doi.org/10.1186/s43162-020-00020-1
Related Papers
Antiangiogenic role of natural flavonoids and their molecular mechanism: an update
Gowtham Kumar Subbaraj; Yasam Santhosh Kumar; Langeswaran Kulanthaivel · 2021
34
cites
391
Bridging autoinflammatory and autoimmune diseases
Emad M. El-Shebiny; Enas S. Zahran; Sabry A. Shoeib; Eman S. Habib · 2021
30
cites
390
Factors affecting glycemic control among Egyptian people with diabetes attending primary health care…
Mai Mohamed Azzam; Adel Alwehedy Ibrahim; Mohammed I. Abd El-Ghany · 2021
27
cites
394
A narrative review of pox: smallpox vs monkeypox
Samiksha Jayswal; Jagdish Kakadiya · 2022
23
cites
390
Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically venti…
Mohammed Abdel Monem Saeed; Alaa Hussein Mohamed; Ahmed Hassan Owaynat · 2022
20
cites
394
Access
View Full Text via DOI
Published in
ISSN 1110-7782
Quartile Q2
AMS Score 94
Field Medicine & Health Sciences
Publisher Springer (Biomed Central Ltd.)
Country 🇪🇬 Egypt
View Journal Profile →
Authors
Publication Details
Year 2020
Language English
Added 14 Aug 2026